MoonLake Immunotherapeutics Reports $61.8 Million Net Loss in Q2 2026

MoonLake Immunotherapeutics reported its financial results for the second quarter of 2026, revealing a net loss of $61.8 million, compared to a loss of $56.1 million in the same period last year. For the first half of 2026, the company incurred a net loss of $131.5 million, a significant increase from the $96.6 million loss recorded in the first half of 2025. The increase in losses is attributed to higher research and development expenses, which rose by 21.5% to $104.7 million, driven by costs associated with clinical trials for its lead product, Sonelokimab (SLK). General and administrative expenses also increased by 22.7% to $26.9 million, reflecting higher personnel and marketing costs.

In terms of financial position, MoonLake's total assets increased to $573.9 million as of June 30, 2026, up from $424.4 million at the end of 2025. The company reported cash and cash equivalents of $477.9 million, a notable increase from $334.5 million at the end of the previous fiscal year. This increase in liquidity is primarily due to successful capital raises, including a public offering in June 2026 that generated approximately $189.8 million in net proceeds. The company also executed an at-the-market offering, raising an additional $50.3 million during the quarter.

Operationally, MoonLake is focused on advancing SLK, a tri-specific Nanobody targeting inflammatory skin and joint diseases. The company recently announced positive results from its Phase 3 VELA trials for hidradenitis suppurativa, with 67.2% of patients achieving significant clinical responses at week 52. Additionally, the company is preparing for the submission of a Biologics License Application (BLA) for SLK, expected by the end of Q3 2026, with a potential commercial launch in the U.S. anticipated in the second half of 2027.

MoonLake's employee headcount has also increased, reflecting its growth strategy as it expands its clinical and administrative teams to support ongoing and future trials. As of June 30, 2026, the company had 83.6 million Class A Ordinary Shares outstanding, up from 71.4 million at the end of 2025, indicating a strategic move to bolster its equity base for future funding needs.

Looking ahead, MoonLake expects to continue incurring substantial operating losses as it invests in the development of SLK and prepares for its commercial launch. The company believes its current cash reserves will be sufficient to fund operations through mid-2028, although it acknowledges the need for additional capital to support ongoing clinical trials and potential commercialization efforts. The company remains focused on achieving regulatory approvals and expanding its product pipeline to address unmet medical needs in inflammatory diseases.